EmERGING STRAIN IS REFERRED TO AS ORTH !MERICAN PULSED FIELD FIELDolvingly recognised as a community-associated disease. The is mainly known as a healthcare-associated disease, but it is also largely associated with healthcare settings. This strain has been proposed by the European Centre of Disease Prevention and Control (ECDC) to identify severe cases of CDAD and to differentiate community-associated cases from nosocomial CDAD.

Recent outbreaks of Clostridium difficile-associated diarrhoea (CDAD) with increased severity, high relapse rate and significant mortality have been related to the emergence of a new, hypervirulent C. difficile strain in North America, Japan and Europe. Definitions of hypervirulent strains have been proposed by the European Centre of Disease Prevention and Control (ECDC) to identify severe cases of CDAD and to differentiate community-associated cases from nosocomial CDAD. The emerging strain is referred to as North American pulsed-field type 1 (NAP1) and PCR ribotype 027. Since 2005, individual countries have developed surveillance studies to monitor the spread of this strain. C. difficile type 027 has caused outbreaks in England and Wales, Ireland, the Netherlands, Belgium, Luxembourg, and France, and has also been detected in Austria, Scotland, Switzerland, Poland and Denmark. Preliminary data indicated that type 027 was already present in historical isolates collected in Sweden between 1997 and 2001.

Introduction
A highly virulent variant of Clostridium difficile is emerging throughout Europe. This strain is characterised as toxontype III, North American pulsed field gel electrophoresis type 1 (NAP1), restriction endonuclease analysis group BI and PCR ribotype 027 [1,2,3]. The type 027 strain carries the binary toxin gene, has an 18bp deletion in the regulatory gene tcdC, and a 1bp deletion at position 117 of tcdC, resulting in a frameshift mutation that potentially allows for larger amounts of toxins to be produced. It is assumed that the increased virulence of this strain is associated with higher amounts of toxin production [4]. Clinical response rates are reduced following treatment with metronidazole or vancomycin [5,6]. This 027 type strain was first isolated in 1988 in France and is considered a 'historical isolate', since it was susceptible to fluoroquinolones and erythromycin [7]. It only accounted for sporadic cases of C. difficile-associated disease (CDAD) until 2002. It has been suggested that the recent acquisition of resistance to the newer fluoroquinolones by the 027 strain was the major reason for its wide dissemination [1,2] although this phenotype is not uncommon in other C. difficile strains [8]. Alternatively, increased virulence resulting in pronounced diarrhoeal symptoms may have promoted spread and cross-infection within healthcare institutions. Since 2002, it had caused major epidemics of CDAD in hospitals in Canada and also in the United States [1,2,3].

Background
CDAD occurs most often in people whose normal gut flora has been disturbed, for example during antibiotic treatment. The...
The diagnostic methods routinely employed in different European laboratories today are not standardised and vary significantly [1,10]. Most laboratories prefer to detect *C. difficile* specific toxins in faeces. Faeces toxin detection can be performed either by cell cytotoxicity assay or immunological detection. The former is the gold standard, but requires up to two days. Various enzyme-immunoassays are available for immunological detection of *C. difficile* toxins, but their sensitivity and specificity vary enormously. Therefore, a study funded by the European Union (EU) has been launched in order to improve diagnostics of CDAD (LSHE-CT-2006-037870: European approach to combat outbreaks of CDAD by development of new diagnostic tests).

**Surveillance efforts**

The European Study Group for *Clostridium difficile* (ESGCD) performed a two-month surveillance study in 2005 on the prevalence of CDAD due to *C. difficile* 027 in 12 EU member states [11]. Based on these data and the recently published background document supported by the ECDC, individual countries have developed surveillance studies to the spread of type 027 in their country [1]. *C. difficile* type 027 causes outbreaks in the United Kingdom (UK) (since 2003 [12]), the Netherlands (since 2003 [13,14]), Belgium (since 2003 [15,16]), France (since 2006 [17,18]), and has also been detected in Austria (2006 [19]), Japan (2005 [20]) and Ireland [21]. In addition, it has been found in Switzerland (AF Widmer, R Frei, M Rupnik, personal communication), Luxembourg (P Reichert, E Kuiper, personal communication), Poland (H Pituch, E Kuiper, personal communication), and Denmark [22] (Figure). Preliminary data presented at the 2nd International *Clostridium difficile* symposium in Maribor, Slovenia (6-9 June, 2007) indicated that type 027 was present in three of more than 1,500 historical isolates collected in Sweden between 1997 and 2001. These strains were sensitive to fluoroquinolones and resemble the pre-outbreak type 027 strains in the United States [2] and France [7].

In England, a mandatory surveillance programme of CDAD in people aged 65 years and over has been included in the healthcare-associated infection surveillance system for acute hospital trusts (UK hospitals are managed by acute trusts; for a detailed definition see: http://www.info.doh.gov.uk/nhsfactsheets/nst/vwHelp/Acute%20trusts?OpenDocument) since January 2004. Some 55,681 cases were reported in 2006. This represents an 8% increase in CDAD cases from 2005 to 2006, after a 17% increase from 2004 to 2005. The mandatory surveillance is operated by the Health Protection Agency (HPA) on behalf of the Department of Health (DH). Epidemiological data are collected quarterly from each of the 169 acute National Health Service (NHS) trusts that treat adult patients and yearly reports are produced by the HPA [23]. CDAD incidence rates of individual trusts are publicly reported each year by the DH [24]. Through its network of regional laboratories in collaboration with the Anaerobe Reference Laboratory (ARL) in Cardiff, the HPA obtained further isolates of *C. difficile* from symptomatic patients in a structured but random sampling scheme. In an allocated week, local hospitals within each of the nine HPA regions were asked to submit a maximum of 10 *C. difficile* toxin-positive stools to their regional HPA laboratory to culture *C. difficile*. Isolates of putative *C. difficile* were then forwarded to the ARL for confirmation of identity, susceptibility testing against eight antimicrobial agents and typing by the PCR ribotyping method. The findings have recently been published in *Eurosurveillance* [25]. A laboratory surveillance network in England was established in 2007 to facilitate the early investigation of clusters of CDAD, particularly those associated with severe symptoms.

In October 2005, the National Institute for Public Health and the Environment (RIVM) in the Netherlands published specific CDAD ribotype 027 guidelines for infection control and treatment to be used by hospitals and nursing homes in response to the outbreaks in the Netherlands. Diagnostic facilities were increased and made accessible for hospital microbiologists. All laboratories were recommended to culture *C. difficile* from toxin positive faeces samples and to store the isolates. Microbiologists were requested to send strains to the national Reference laboratory from patients with a severe course of CDAD or when an increased incidence of CDAD was noticed. A National Reference Laboratory for *C. difficile* was established at the Department of Medical Microbiology at the Leiden University Medical Center. Strains were characterised by PCR ribotyping, toxinotyping, presence of toxin genes and antimicrobial susceptibility [26]. The results of the first year of surveillance are currently in press [27].

**Figure**

Distribution of *C. difficile* ribotype 027 in Europe* as of June 2007

* Not all countries have performed surveillance studies to *C. difficile* type 027 and this figure may underestimate the number of affected countries.
to facilitate characterisation of *C. difficile* strains. The Ministry of Health disseminated recommendations for CDAD prevention and control to all hospitals and nursing homes in September 2006. A national, prospective surveillance of CDAD incidence among hospitals will be implemented in 2007 and will include a sampling scheme in order to better assess the geographical dissemination of *C. difficile* strains.

One case of *C. difficile* 027 was identified in Scotland in 2006 by the UK national reference laboratory in Cardiff. A research study in Western Scotland examined 102 additional strains obtained from nine hospitals from 2006 to 2007. None of these were ribotype 027. Mandatory surveillance in line with the English system has been initiated in Scotland in 2006. Data on the incidence of *C. difficile* 027 in people aged 65 years or older are being collected in healthcare institutions in Scotland and will be published in the public domain by the end of 2007.

### Table

*C. difficile* type 027 in 11 European countries (due to differences in surveillance the data cannot be directly compared).

<table>
<thead>
<tr>
<th>Country</th>
<th>Survey period</th>
<th>Total number of inhabitants / hospitals / hospital beds</th>
<th>Number of hospitals positive for 027 / number of hospitals investigated for 027</th>
<th>Number of nursing homes positive for 027</th>
<th>Number of 027 strains / total number of strains tested</th>
<th>Mortality attributable to CDAD</th>
<th>Updates available at:</th>
</tr>
</thead>
<tbody>
<tr>
<td>England and Wales</td>
<td>2005-2006</td>
<td>5.3 million inhab/717 acute trust hosp/35,794 beds: Wales: 95 /11,500</td>
<td>94/170 (55.3%)</td>
<td>n.a</td>
<td>971/n.a</td>
<td>n.a</td>
<td><a href="http://www.hpa.org.uk/infections/topics_az/clostridium_difficile/default.htm">http://www.hpa.org.uk/infections/topics_az/clostridium_difficile/default.htm</a></td>
</tr>
<tr>
<td>Scotland</td>
<td>2006-2007</td>
<td>5.1 million/261 (incl. 45 acute hosp)/29,000</td>
<td>1/9 (11%)</td>
<td>0</td>
<td>1/103 (1%)</td>
<td>n.a</td>
<td><a href="http://www.hsphsc.nhs.uk/haic/sshap/clostridiumdifficile.aspx">http://www.hsphsc.nhs.uk/haic/sshap/clostridiumdifficile.aspx</a></td>
</tr>
<tr>
<td>Ireland</td>
<td>2006</td>
<td>4.2 million/81/10,000</td>
<td>7/7 (100%)</td>
<td>2</td>
<td>81/350 (23.1%)</td>
<td>n.a</td>
<td><a href="http://www.ndsc.ie/hpsc/A-Z/Gastroenteric/CDifficile">http://www.ndsc.ie/hpsc/A-Z/Gastroenteric/CDifficile</a></td>
</tr>
<tr>
<td>France</td>
<td>Jan 2006 – Apr 2007</td>
<td>64 million/ca. 2,800/ca. 460,000</td>
<td>40/16/ (24.3%)</td>
<td>4</td>
<td>277/471 (58.8%)</td>
<td>4% (Northern France only)</td>
<td><a href="http://www.invs.sante.fr/raisin">http://www.invs.sante.fr/raisin</a></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>2005-2006</td>
<td>16.4 million/129/53,000</td>
<td>20/50 (40%)</td>
<td>7</td>
<td>218/863 (25.2%)</td>
<td>6.3%</td>
<td><a href="http://www.rivm.nl/cib/infectieziekten/Clostridium_difficile/Clostridium_difficile_draaitoek.jsp">http://www.rivm.nl/cib/infectieziekten/Clostridium_difficile/Clostridium_difficile_draaitoek.jsp</a></td>
</tr>
<tr>
<td>Belgium</td>
<td>2005-2006</td>
<td>10 million/113/51,640</td>
<td>38/78 (48.7%)</td>
<td>n.a</td>
<td>190/814 (23%)</td>
<td>n.a</td>
<td><a href="http://www.belgianinfectioncontrolsociety.be">http://www.belgianinfectioncontrolsociety.be</a></td>
</tr>
<tr>
<td>Poland</td>
<td>2005</td>
<td>38 million/781/184,000</td>
<td>1/1 (100%)</td>
<td>n.a</td>
<td>1/175 (0.6%)</td>
<td>n.a</td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>2006</td>
<td>8.2 million/264/63,2,648</td>
<td>1/20 (5%)</td>
<td>n.a</td>
<td>1/102 (1%)</td>
<td>n.a</td>
<td></td>
</tr>
<tr>
<td>Luxembourg</td>
<td>2006</td>
<td>0.45 million/10/2100</td>
<td>4/10 (40%)</td>
<td>n.a</td>
<td>18/75 (24%)</td>
<td>n.a</td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>2005-2006</td>
<td>7.3 million/337/28,080</td>
<td>3/11 (27%)</td>
<td>1</td>
<td>4/211 (1.7%)</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>Nov 2006-March 2007</td>
<td>5.4 million/69/22,604</td>
<td>n.a</td>
<td>n.a</td>
<td>6 (pilot study)</td>
<td>Study in progress</td>
<td></td>
</tr>
</tbody>
</table>

n.a: data not available.

In Belgium, the Scientific Institute of Public Health (IPH) and the national reference laboratory (Université catholique de Louvain) set up a laboratory-based surveillance of CDAD clusters in January 2006. Laboratories are requested to send in strains, when two or more CDAD cases occur in the same department within a period of one month. In parallel, a prospective surveillance of CDAD incidence was set up in Belgian acute care hospitals in collaboration with the Belgian Infection Control Society (BICS). Hospitals report clinical and risk factor data on all CDAD cases as well as denominator data on a web-based data entry form during a six month surveillance period. Hospitals are also requested to send strains of five consecutive CDAD patients to the reference laboratory for species confirmation, detection of the *tcdC* deletion and the binary toxin, toxinotyping, PCR ribotyping and determination of antimicrobial susceptibility. National guidelines for prevention and control of CDAD in hospitals and nursing homes were issued by the BICS in June 2006.
The available results from the surveillance efforts of 11 European countries are summarised in the Table. As methodology, time period and geographical coverage of surveillance differ significantly from one country to another, these results are qualitative and cannot be used for purposes of comparison. A new surveillance study among all European member states, planned for 2007-2008, is currently being developed by ECDC in collaboration with ESGCD, a study group for Clostridium difficile set up by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). In addition, a specific surveillance programme (CDAD-KISS) has recently been launched in Germany.

**Conclusion**

*C. difficile* type 027 has been detected in an increasing number of European countries. This could either be due to the fact that more countries have started surveillance surveys or an indication that type 027 is spreading rapidly. As yet, type 027 has affected healthcare facilities in 11 EU member states and in Switzerland (Figure). Increased awareness is necessary in all member states and surveillance studies should be performed with uniform definitions, as proposed by ECDC [1]. A guidance document for infection control measures has recently been prepared by international experts together with ECDC [28]. It is unknown how many CDAD cases in nursing homes and the community are due to type 027. The situation in those settings warrants more attention in the future.

**References**


